Antiretroviral Drug Resistance

• Importance of Resistance Testing and Therapeutic Drug Monitoring for Treatment Success (Symposium 142)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• NNRTI Resistance Can Occur in the Absence of Known Mutations (Slide H-451)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• FTC Similar in Most Ways to 3TC (Poster H-908)
  Coverage by Benjamin Young, M.D., Ph.D.

• Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (Poster H-910)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

Structured Treatment Interruptions

• Structured Treatment Interruptions Successful With Patients Who Have High CD4 Counts (Slide H-448)
  Coverage by Gerald Pierone, Jr., M.D.

• CD4-Guided Treatment Interruptions: A New Therapeutic Strategy (Poster H-856)
  Coverage by Gerald Pierone, Jr., M.D.

• Negative Impact of Drug Holidays in HIV-Infected Patients on NNRTIs (Poster H-857)
  Coverage by Gerald Pierone, Jr., M.D.

Antiretroviral Drugs for Initial Therapy

• Abacavir Not Inferior to AZT in Treatment-Naive Patients (Slide H-446)
  Coverage by Keith Henry, M.D.

• Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (Poster H-838)
  Coverage by Andrew T. Pavia, M.D.

• Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (Poster H-839)
  Coverage by Benjamin Young, M.D., Ph.D.

• No Major Renal Problems With Tenofovir Were Identified in the Naive Population Evaluated in the GS 903 Study (Poster H-840)
  Coverage by Edwin DeJesus, M.D.

• A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (Poster H-841)
  Coverage by Judith A. Aberg, M.D.

• Kaletra "Monotherapy" Safe and Efficacious for Treatment-Naive Patients (Poster H-845)
  Coverage by Gerald Pierone, Jr., M.D.

• Switching From PI to Nevirapine in Patients With Undetectable Viral Load Is Safe and Potent (Poster H-846)
  Coverage by Judith A. Aberg, M.D.

• No Detectable Difference in Efficacy Seen Between Efavirenz and Nevirapine (Poster H-848)
  Coverage by Andrew T. Pavia, M.D.

• Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (Poster H-849)
  Coverage by Gerald Pierone, Jr., M.D.

• Recent Advances in the Clinical Management of the Antiretroviral-Naive Patient (Symposia 1120)
  Coverage by Judith A. Aberg, M.D.

• Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (Slide H-1722a)
  Coverage by Calvin J. Cohen, M.D., M.S.

• Can Abacavir Be Given Once-a-Day? (Slide H-1722b, Poster A-1797)
  Coverage by Benjamin Young, M.D., Ph.D.

Complications of HIV Disease

• Overview of Metabolic Complications in HIV Disease (Meet-the-Experts 1281, 1282)
  Coverage by Keith Henry, M.D.

• Longer Dosing Intervals of Epoetin Alfa Are Effective in Maintaining Hemoglobin Levels in Anemic, HIV-Infected Patients (Poster H-1919)
  Coverage by Robert J. Frascino, M.D.

• Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Side Effects of Antiretroviral Therapy (Poster H-2013)
  Coverage by Keith Henry, M.D.

Management of Treatment-Experienced Patients

• Risk of Death Following Triple-Class Virological Failure (Slide H-450)
  Coverage by Keith Henry, M.D.

• Managing Patients After Virologic Failure (Symposia 1121)
  Coverage by Judith A. Aberg, M.D.

Drug-Drug Interactions

• Pharmacokinetic Interactions of 908 (Poster A-1607)
  Coverage by Edwin DeJesus, M.D.

• High Dose of Vitamin C Significantly Reduces Indinavir Levels in Pilot Study (Poster A-1610)
  Coverage by Myles Helfand

• A Look at Tenofovir Drug-Drug Interactions (Posters A-1615, A-1617, A-1618)
  Coverage by Paul E. Sax, M.D.

• No PK Interaction Seen Between FTC and AZT or Tenofovir (Posters A-1620, A-1621)
  Coverage by Andrew T. Pavia, M.D.

HIV Coinfection

• HAART Often Successful in HIV/HCV Coinfected Patients -- If They Can Stay on Treatment (Poster H-826)
  Coverage by Timothy Wilkin, M.D., M.P.H.

New Antiretroviral Agents

• T-1249 Retains Potent Short-Term Antiviral Activity in Patients Who Have Failed a Regimen Containing T-20 (Slide H-444)
  Coverage by Calvin J. Cohen, M.D., M.S.

• Early Pre-Clinical Development of GW8248 Promising (Slide H-445)
  Coverage by Andrew T. Pavia, M.D.

• 908 Plus Lopinavir/Ritonavir Does Not Appear to Be a Viable Regimen for HIV-Infected Patients (Poster H-855A)
  Coverage by Edwin DeJesus, M.D.

• Dyslipidemia: Change to Tenofovir? (Poster H-855B)
  Coverage by Calvin J. Cohen, M.D., M.S.

• FTC Compares Well to 3TC in Triple-NRTI Regimens (Poster H-868)
  Coverage by Corklin R. Steinhart, M.D., Ph.D.